Donoghue Forlines’s Jazz Pharmaceuticals JAZZ Stock Holding History

Donoghue Forlines’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,192	Closed	-$272K	–	257
2023 Q2	$272K	Buy	+2,192	New	+$295K	0.09%	231
2023 Q1	–	Sell	-9,875	Closed	-$1.57M	–	240
2022 Q4	$1.57M	Buy	9,875 +8,356	+550%	+$1.22M	0.56%	37
2022 Q3	$202K	Sell	1,519 -2,675	-64%	-$407K	0.07%	231
2022 Q2	$654K	Buy	+4,194	New	+$646K	0.17%	151
2021 Q3	–	Sell	-3,792	Closed	-$674K	–	222
2021 Q2	$674K	Sell	3,792 -23	-0.6%	-$3.98K	0.13%	166
2021 Q1	$627K	Sell	3,815 -569	-13%	-$93.6K	0.12%	170
2020 Q4	$724K	Buy	+4,384	New	+$653K	0.14%	177

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Donoghue Forlines's JAZZ Position: Q3 2023 in Review

Donoghue Forlines sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 2,192 shares — an estimated $272K sold.

Donoghue Forlines first reported a position in JAZZ in Q4 2020 and held it in 7 quarters. The position peaked at $1.57M in Q4 2022. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

Donoghue Forlines reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Donoghue Forlines sold 2,192 Jazz Pharmaceuticals shares in Q3 2023, an estimated $272K.
Donoghue Forlines first reported a position in Jazz Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Donoghue Forlines's Jazz Pharmaceuticals position peaked at $1.57M in Q4 2022.
484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Donoghue Forlines's 13F filing for Q3 2023, filed 6 Nov 2023.